A number of research firms have changed their ratings and price targets for Sagimet Biosciences (NASDAQ: SGMT):
- 11/13/2026 – Sagimet Biosciences had its “sell” rating reaffirmed by The Goldman Sachs Group.
- 11/13/2026 – Sagimet Biosciences had its “market outperform” rating reaffirmed by Citigroup.
- 11/13/2026 – Sagimet Biosciences was given a new $27.00 price target by Wells Fargo & Company.
- 11/13/2026 – Sagimet Biosciences had its price target lowered by Canaccord Genuity Group from $56.00 to $50.00. They now have a “buy” rating on the stock.
- 10/15/2026 – Sagimet Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/5/2026 – Sagimet Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
- 10/2/2026 – Sagimet Biosciences had its price target raised by Guggenheim from $25.00 to $26.00. They now have a “buy” rating on the stock.
- 10/1/2026 – Sagimet Biosciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 10/1/2026 – Sagimet Biosciences had its “market outperform” rating reaffirmed by Citigroup.
- 10/1/2026 – Sagimet Biosciences had its price target raised by Oppenheimer from $33.00 to $38.00. They now have an “outperform” rating on the stock.
- 10/1/2026 – Sagimet Biosciences had its price target lowered by Citizens Jmp from $29.00 to $27.00. They now have a “market outperform” rating on the stock.
- 9/28/2026 – Sagimet Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
- 9/24/2026 – Sagimet Biosciences is now covered by The Goldman Sachs Group. They set a “sell” rating and a $7.00 price target on the stock.
- 9/24/2026 – Sagimet Biosciences is now covered by The Goldman Sachs Group. They set a “sell” rating and a $7.00 price target on the stock.
Sagimet Biosciences Price Performance
Shares of NASDAQ SGMT opened at $10.22 on Monday. Sagimet Biosciences Inc. has a one year low of $4.50 and a one year high of $11.45. The business’s fifty day moving average price is $9.88 and its 200-day moving average price is $7.69. The stock has a market capitalization of $635.28 million, a PE ratio of -8.59 and a beta of 3.43.
Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05). As a group, equities analysts expect that Sagimet Biosciences Inc. will post -1.14 EPS for the current fiscal year.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.
Read More
- Five stocks we like better than Sagimet Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Sagimet Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
